Generate Biomedicines (NASDAQ:GENB) Sees Large Volume Increase – Here’s What Happened

Generate Biomedicines Inc (NASDAQ:GENB) saw an uptick in trading volume on Wednesday . Approximately 836,226 shares were traded during mid-day trading, an increase of 16% from the previous session’s volume of 719,495 shares.The stock last traded at $18.1910 and had previously closed at $20.38.

Analyst Ratings Changes

GENB has been the subject of a number of analyst reports. HC Wainwright increased their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Morgan Stanley increased their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Finally, Weiss Ratings started coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They set a “sell (d)” rating on the stock. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Trading Down 13.9%

The stock has a market cap of $2.25 billion and a P/E ratio of -11.03. The company’s 50 day moving average is $15.19.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. As a group, research analysts predict that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Generate Biomedicines

A number of institutional investors and hedge funds have recently made changes to their positions in GENB. Braidwell LP purchased a new position in shares of Generate Biomedicines during the second quarter valued at approximately $55,398,000. Bank of New York Mellon Corp purchased a new stake in shares of Generate Biomedicines in the 2nd quarter worth approximately $967,000. AXQ Capital LP bought a new position in Generate Biomedicines during the 2nd quarter valued at approximately $218,000. Susquehanna International Group LLP bought a new position in Generate Biomedicines during the 2nd quarter valued at approximately $196,000. Finally, California State Teachers Retirement System purchased a new position in Generate Biomedicines during the second quarter valued at $96,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.